Multiple Sites Activated for Ph 1b/2 Trial of AMXT 1501 and DFMO in Patients with solid tumors including Breast Cancer and Melanoma February 9, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
AstraZeneca announced $15B investment in China through 2030 to expand medicines manufacturing and R&D February 1, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Gen Bi-and Multi-Functional Fusion Protein Pipeline February 1, 2026
Key Patent Filed and Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors Unveiled February 1, 2026
Eikon Therapeutics Secures $350.7M Series D to Advance Clinical-Stage Programs and Future Pipeline February 1, 2026
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V–mutated solid tumors February 1, 2026
Janux Therapeutics and Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors January 25, 2026
Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers January 25, 2026
MediLink Therapeutics and Roche to develop and commercialize YL201 across numerous solid tumor types January 18, 2026
Summit Therapeutics and GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 ADC January 18, 2026
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop RC148 for Advanced Solid Tumors January 18, 2026
Tahoe Therapeutics and Alloy Therapeutics to Form Joint Venture and Develop First-in-Class ADCs for Hard-to-Treat Cancers January 18, 2026
IND application submitted for GTB-5550 TriKE for B7-H3 expressing solid tumor cancers January 18, 2026
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development January 11, 2026
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration January 11, 2026
